1.
|
Ferlay J, Bray F, Pisani P and Parkin DM;
GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence
Worldwide. IARC Press. Lyon: 2004.
|
2.
|
Dowsett M and Dunbier AK: Emerging
biomarkers and new understanding of traditional markers in
personalized therapy for breast cancer. Clin Cancer Res.
14:8019–8026. 2008. View Article : Google Scholar : PubMed/NCBI
|
3.
|
Altieri DC: Molecular cloning of effector
cell protease receptor-1, a novel cell surface receptor for the
protease factor Xa. J Biol Chem. 269:3139–3142. 1994.PubMed/NCBI
|
4.
|
Altieri DC: Splicing of effector cell
protease receptor-1 mRNA is modulated by an unusual retained
intron. Biochemistry. 33:13848–13855. 1994. View Article : Google Scholar : PubMed/NCBI
|
5.
|
Mita AC, Mita MM, Nawrocki ST and Giles
FJ: Survivin: key regulator of mitosis and apoptosis and novel
target for cancer therapeutics. Clin Cancer Res. 14:5000–5005.
2008. View Article : Google Scholar : PubMed/NCBI
|
6.
|
Ambrosini G, Adida C and Altieri DC: A
novel antiapoptosis gene, survivin expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
7.
|
Adida C, Crotty PL, McGrath J, et al:
Developmentary regulated expression of the novel cancer
antiapoptosis gene survivin in human and mouse differentiation. Am
J Pathol. 152:43–49. 1998.PubMed/NCBI
|
8.
|
Olie RA, Simões-Wüst AP, Baumann B, et al:
A novel antisense oligonucleotide targeting survivin expression
induces apoptosis and sensitizes lung cancer cells to chemotherapy.
Cancer Res. 60:2805–2809. 2000.
|
9.
|
Sah NK, Khan Z, Khan GJ and Bisen PS:
Structural, functional and therapeutic biology of survivin. Cancer
Lett. 244:164–171. 2006. View Article : Google Scholar : PubMed/NCBI
|
10.
|
O'Driscoll L, Linehan R, Kennedy MS, et
al: Lack of prognostic significance of survivin, survivin-ΔEx3,
survivin-2B, galectin-3, bag-1, bax-α and MRP-1 mRNAs in breast
cancer. Cancer Lett. 201:225–236. 2003.
|
11.
|
Hinnis AR, Luckett JCA and Walker RA:
Survivin is an independent predictor of short-term survival in poor
prognostic breast cancer patients. Br J Cancer. 96:639–645. 2007.
View Article : Google Scholar : PubMed/NCBI
|
12.
|
Tanaka K, Iwamoto S, Gon G, et al:
Expression of survivin and its relationship to loss of apoptosis in
breast carcinomas. Clin Cancer Res. 6:127–134. 2000.PubMed/NCBI
|
13.
|
Bertheau P, Espié M, Turpin E, et al: TP53
status and response to chemotherapy in breast cancer. Pathobiology.
75:132–139. 2008. View Article : Google Scholar : PubMed/NCBI
|
14.
|
Brennan DJ, Rexhepaj E, O'Brien SL, et al:
Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic
indicator in breast cancer. Clin Cancer Res. 14:2681–2689. 2008.
View Article : Google Scholar : PubMed/NCBI
|
15.
|
Hayward JL, Carbone PP, Heusen JC, et al:
Assessment of response to therapy in advanced breast cancer. Br J
Cancer. 35:292–298. 1977. View Article : Google Scholar : PubMed/NCBI
|
16.
|
Sataloff DM, Mason BA, Prestipino AJ, et
al: Pathologic response to induction chemotherapy in locally
advanced carcinoma of the breast: a determinant of outcome. J Am
Coll Surg. 180:297–306. 1995.PubMed/NCBI
|
17.
|
Li F and Ling X: Survivin study: an update
of ‘what is the next wave’? J Cell Physiol. 208:476–486. 2006.
|
18.
|
Dohi T, Beltrami E, Wall NR, Plescia J and
Altieri DC: Mitochondrial survivin inhibits apoptosis and promotes
tumorigenesis. J Clin Invest. 114:1117–1127. 2004. View Article : Google Scholar : PubMed/NCBI
|
19.
|
Li XN, Shu Q, Su JM, et al: Differential
expression of survivin splice isoforms in medulloblastomas.
Neuropathol Appl Neurobiol. 33:67–76. 2007.PubMed/NCBI
|
20.
|
Altieri DC and Marchisio PC: Survivin
apoptosis: an interloper between cell death and cell proliferation
in cancer. Lab Invest. 79:1327–1333. 1999.PubMed/NCBI
|
21.
|
Kennedy SM, O'Driscoll L, Purcell R, et
al: Prognostic importance of survivin in breast cancer. Br J
Cancer. 88:1077–1083. 2003. View Article : Google Scholar : PubMed/NCBI
|
22.
|
Ponnelle T, Chapusot C, Martin L, et al:
Cellular localisation of survivin: impact on the prognosis in
colorectal cancer. J Cancer Res Clin Oncol. 131:504–510. 2005.
View Article : Google Scholar : PubMed/NCBI
|
23.
|
Xie D, Zeng YX, Wang HJ, et al: Expression
of cytoplasmic and nuclear survivin in primary and secondary human
glioblastoma. Br J Cancer. 94:108–114. 2006. View Article : Google Scholar : PubMed/NCBI
|
24.
|
Piras F, Murtas D, Minerba L, et al:
Nuclear survivin is associated with disease recurrence and poor
survival in patients with cutaneous malignant melanoma.
Histopathology. 50:835–842. 2007. View Article : Google Scholar : PubMed/NCBI
|
25.
|
Mirza A, McGuirk M, Hockenberry TN, et al:
Human survivin is negatively regulated by wild-type p53 and
participates in p53-dependent apoptotic pathway. Oncogene.
21:2613–2622. 2002. View Article : Google Scholar : PubMed/NCBI
|